Michael Milone
University of Pennsylvania
H-index: 64
North America-United States
Top articles of Michael Milone
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells | 2024/2/20 | ||
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines | Blood Advances | Guido Ghilardi Luca Paruzzo Jakub Svoboda Elise A Chong Alexander A Shestov | 2024/2/13 |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells | 2024/2/13 | ||
Methods and compositions for cells expressing a chimeric intracellular signaling molecule | 2024/2/6 | ||
Evaluating the relationship of affinity, functional avidity, and in vivo potency in KIR-CAR T cells | Cancer Research | Jun Xu Selene Nunez-Cruz John M Leferovich Gayathri Gulendran Chune Zhang | 2024/3/22 |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | 2022/3/16 | ||
Regulatable chimeric antigen receptor | 2023/2/14 | ||
Sammensætninger og fremgangsmåder til selektiv ekspression af kimære antigenreceptorer | 2023/5/22 | ||
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells | Nature biotechnology | Sangwook Oh Xuming Mao Silvio Manfredo-Vieira Jinmin Lee Darshil Patel | 2023/9 |
F77 antigen is a promising target for adoptive T cell therapy of prostate cancer | Biochemical and Biophysical Research Communications | Payal Grover Selene Nunez-Cruz John Leferovich Tyra Wentz Atrish Bagchi | 2023/11/5 |
Uso de uma célula | 2023/12/12 | ||
Apparatus | 2022/9/29 | ||
Activation and Expansion of T Cell Subsets Using Biocompatible Solid Substrates with Tunable Rigidity | 2023/5/4 | ||
CD38 as a pan-hematologic target for chimeric antigen receptor T cells | Blood Advances | Tina Glisovic-Aplenc Caroline Diorio John A Chukinas Kimberly Veliz Olga Shestova | 2023/8/22 |
321 Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesothelioma | Jun Xu Selene Nunez-Cruz Jacqueline Rivera Michael Milone Laura Johnson | 2023/11/1 | |
Composição farmacêutica | 2023/12/5 | ||
Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy | Blood Cancer Discovery | Alfred L Garfall Adam D Cohen Sandra P Susanibar-Adaniya Wei-Ting Hwang Dan T Vogl | 2023/3/1 |
Treatment of cancer using a cd123 chimeric antigen receptor | 2023/7/13 | ||
Compositions and methods of chimeric autoantibody receptor t cells | 2023/9/28 | ||
Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy | Blood | Adam D Cohen Wei-Ting Hwang Sandra Susanibar-Adaniya Dan T Vogl Alfred L Garfall | 2023/11/28 |
